Panbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer, Exceeding Anticipated Timelines with Accelerated Momentum

Stock Information for Panbela Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Panbela Therapeutics Inc.

Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025
Panbela Announces Poster Presentation at American Association for Cancer Research:
Panbela Announces Transfer to OTCQB Market
Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results
Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024
Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements
Panbela Announces Closing of Approximately $9.0 Million Public Offering
Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.